In cell and gene therapy (CGT) and recombinant protein drug development, the microbial cell bank serves as the starting material for manufacturing. Its genetic stability, purity, and traceability directly determine process consistency and product safety. Common root causes of IND delays often center on: a mismatch between testing protocols and project stage, genetic stability data not covering actual production passages, insufficiently designed consistency strategies between MCB and WCB, and undetected phage or cryptic contamination. Therefore, microbial cell bank release should not be viewed as a one-time testing task, but as a quality control system dynamically designed around regulatory submission and manufacturing objectives.
During project progression, clients frequently encounter these critical nodes:
Does my MCB data meet IND requirements?
Does WCB require full characterization or only consistency confirmation?
Should WGS be introduced at the current stage?
Are process fluctuations during fermentation caused by genetic drift or contamination?
The essence of these issues lies not in the testing itself, but in the evidence chain construction strategy. Creative Biogene's microbial cell bank release service focuses on aligning data with both regulatory expectations and project stage precision.
| Project Stage | Typical Strategic Focus | Commonly Included Testing Items |
| Early R&D / Process development | Rapid Release | Strain identification, purity confirmation, phage detection, partial genotype/phenotype, and basic genetic stability. Optimized for turnaround. |
| Pre-IND submission / GMP manufacturing | Advanced Release | Full scope: strain ID, purity, phage detection, extended genotype/phenotype analysis, complete genetic stability, and adventitious agent detection. Designed for IND/BLA regulatory requirements. |
| Routine release / Early submission preparation | Core Release | Strain identification, purity confirmation, phage detection, and basic genetic stability. Establishes baseline quality data while controlling key risks. |
For Rapid Release: longer lead-time tests (e.g., complete genetic stability) may be performed as subsequent supplemental data to balance timeliness and compliance.
| Testing Item | Core Release | Advanced Release | Rapid Release |
| Strain identification | ✓ | ✓ | ✓ |
| Purity confirmation | ✓ | ✓ | ✓ |
| Phage detection | ✓ | ✓ | ✓ (rapid strategy) |
| Genotype/phenotype analysis | ✓ | ✓ (extended) | Partial |
| Genetic stability | ✓ (basic) | ✓ (complete) | Parallel execution |
| Adventitious agent detection | — | ✓ | — |
For specific methods, parameters, or pricing, please contact our technical team for a customized proposal.
Based on our understanding of regulatory guidelines and industry-standard expectations for IND-enabling studies, we have structured microbial cell bank release into a system centered on "risk identification – strategy design – data support".
Compliance framework
Built on ICH Q5A (viral safety), Q5B (genetic stability), and Q5D (cell substrate characterization), with operations following GLP principles and aligned with relevant cGMP expectations where applicable. Data management follows ALCOA+ principles and 21 CFR Part 11 for electronic records, with full LIMS traceability and independent QA review for each batch.
Method validation
Compendial methods (USP, Ph. Eur.) are qualified for their intended use; method suitability is verified under actual testing conditions. Non-compendial methods are validated in parallel with compendial methods, with complete validation reports provided.
Environmental control
Physical segregation and unidirectional workflow separate sample handling, culture, and molecular detection. Dedicated areas and independent biosafety cabinets for phage work, with periodic environmental monitoring.
Submission-ready reporting
Reports are designed with IND/BLA submission as the endpoint, including method descriptions, raw data, and compliance statements, ready for direct inclusion in CMC documentation.
We have established an integrated technology platform covering microbiology, molecular biology, and sequencing, supporting the full testing workflow from rapid screening to in-depth analysis.
| Platform | Key Equipment / Capability | Description |
| Microbiology | BSC, multi-zone incubators, anaerobic workstation, automated colony counter | Batch sample processing, multi-environment culture (aerobic/anaerobic/microaerophilic); automated counting reduces bias |
| Molecular Biology | qPCR, digital PCR (ddPCR) | High-throughput gene quantification, low-abundance target detection – copy number analysis, rapid mycoplasma screening |
| Sequencing | Sanger sequencer, Illumina NGS | Single-gene sequencing to whole genome sequencing (WGS); low-frequency mutation detection, genetic stability |
| Mass Spectrometry | MALDI-TOF MS | Rapid strain identification covering major industrial microbial species; pre-release rapid screening |
| Flow Cytometry | Flow cytometer | LIVE/DEAD staining for rapid viability assessment; identifies VBNC state, assists CFU count interpretation |
Supports MCB/WCB release in alignment with ICH Q5D principles for cell substrate characterization and USP general chapters for identity testing.
Purity confirmation and viable count; used for master and working cell bank purity verification.
Industry-accepted double-layer agar plaque assay applied for MCB/WCB release, supporting contamination control strategy as recommended by FDA Guidance for Industry
Antibiotic resistance and auxotrophy verification; applied for cell bank construction and change evaluation.
Monitoring from MCB through WCB to EOP, in accordance with ICH Q5B.
If you are preparing for microbial cell bank release or have uncertainties at critical decision points, now is the best time to front-load risks and validate proactively.
We will systematically design a testing strategy and method combination tailored to your project stage, strain characteristics, and application scenario – ensuring every decision is supported by robust data, enhancing release certainty and controllability from the very start. Contact us today to request your customized microbial cell bank release testing plan.
Q: What is the difference between MCB and WCB testing requirements?
A: The core difference is that MCB requires full characterization, while WCB focuses on verifying consistency with MCB. As the manufacturing source, MCB must cover identity, purity, genetic stability, and the absence of adventitious agents comprehensively. WCB generally does not need to repeat all tests; rather, it needs to confirm that critical quality attributes remain consistent. We typically recommend completing deep testing (e.g., WGS) at the MCB stage, followed by a streamlined strategy for WCB – this aligns with ICH Q5D and effectively controls downstream cost and timeline.
Q: Is whole genome sequencing (WGS) mandatory?
A: Not mandatory, but it is generally recommended before IND or at key stages. WGS offers higher resolution for detecting low-frequency mutations and genetic drift compared to traditional PCR methods, and may be requested by regulators on a case-by-case basis, depending on product complexity and manufacturing process. In actual reviews, regulators increasingly expect higher resolution genetic data. Our recommendation: optional in early R&D, but introduce WGS before IND submission or scale-up to avoid later time risks from supplemental data.
Q: Is phage detection always necessary?
A: For fermentation or high-density culture projects, it is generally recommended as part of routine testing. Phage contamination is a low-probability but high-impact risk – once it occurs, it can cause fermentation system collapse in a short time. Although not uniformly mandated by regulations, contamination control strategies receive significant attention during review and production. For projects involving fermentation scale-up or with a history of contamination risk, we usually recommend including phage detection as a routine item, managed with periodic monitoring.
Q: How should strain changes during passaging be handled?
A: The key is not whether changes occur, but whether they are monitored and controlled. Minor genetic drift is inevitable during long-term culture. Regulators focus more on whether functionality or expression is affected and whether a systematic monitoring/evaluation mechanism exists. Typically, we conduct passage experiments combined with sequencing analysis to assess change trends and define acceptable ranges. If changes impact critical quality attributes, reversion to MCB or re-banking is required.
Copyright © 2026 Creative Biogene. All rights reserved.